Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Open Access
- 23 May 2011
- journal article
- case report
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 11 (1) , 30
Abstract
Background: Pulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib. Case presentation: Here, we discuss the relevance of previously published cases and add another well-characterised patient who developed pre-capillary PH under long-term therapy with the multi-tyrosine kinase inhibitor dasatinib approved for therapy of chronic myeloic leukaemia (CML) and Philadelphia chromosome positive acute lymphocytic leukaemia (mean time of all patients on dasatinib: 26 months). Hence, we discuss the possibility of dasatinib itself causing PH after long-term therapy and turn specialist's attention to this possible severe side effect. At present, the true incidence of dasatinib-associated PH remains illusive and systematic data regarding haemodynamics are missing. Conclusion: We therefore recommend systematic screening of dasatinib-treated patients for pulmonary hypertension and subsequent collection of haemodynamic data.Keywords
This publication has 17 references indexed in Scilit:
- Pulmonary Hypertension Associated with Myeloproliferative Disorders: A Retrospective Study of Ten CasesRespiration, 2007
- Recurrence of Severe Pulmonary Hypertension Following the Removal of a Lung AllograftChest, 2007
- Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targetsBlood, 2007
- Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid LeukemiaAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib FailureJournal of Clinical Oncology, 2007
- Long term imatinib treatment in pulmonary arterial hypertensionThorax, 2006
- Imatinib Mesylate in the Treatment of Refractory Idiopathic Pulmonary Arterial HypertensionAnnals of Internal Medicine, 2006
- Reversal of experimental pulmonary hypertension by PDGF inhibitionJournal of Clinical Investigation, 2005
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Anorectic Drugs and Pulmonary Hypertension from the Bedside to the BenchThe American Journal of the Medical Sciences, 2001